Related Experiment Video
Updated: May 11, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Effects of CT-Xp gene knock down in melanoma cell lines
Otavia L Caballero1, Tzeela Cohen, Sita Gurung
1Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, USA. ocaball1@jhmi.edu
Abstract:
Cancer/testis (CT) genes are encoded by genes that are normally expressed only in the human germ line but which are activated in various malignancies. CT proteins are frequently immunogenic in cancer patients and their expression is highly restricted to tumors. They are thus important targets for anticancer immunotherapy. In several different tumor types, the expression of CT-X genes is associated with advanced disease and poor outcome, indicating that their expression might contribute to tumorigenesis. CT-X genes encoding members of the MAGE protein family on Xq28 have been shown to potentially influence the tumorigenic phenotype. We used small interfering RNA (siRNA) to investigate whether CT-X mapping to the short arm of the X-chromosome might also have tumorigenic properties and therefore be potentially targeted by functional inhibitors in a therapeutic setting. siRNAs specific to GAGE, SSX and XAGE1 were used in cell proliferation, migration and cell survival assays using cell lines derived from melanoma, a tumor type known to present high frequencies of expression of CT antigens. We found that of these, those specific to GAGE and XAGE1 most significantly impeded melanoma cell migration and invasion and those specific to SSX4 and XAGE1 decreased the clonogenic survival of melanoma cells. Our results suggest that GAGE, XAGE1 and SSX4 might each have a role in tumor progression and are possible therapeutic targets for the treatment of melanoma and other malignancies.
Insights
Cancer/testis (CT) genes, activated in tumors, are potential immunotherapy targets. Researchers found that inhibiting GAGE, XAGE1, and SSX4 genes significantly impacted melanoma cell progression and survival, suggesting their therapeutic potential.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer/testis (CT) genes are expressed in germ cells but aberrantly activated in various cancers.
- CT proteins are immunogenic, making them promising targets for cancer immunotherapy.
- CT-X genes, particularly those on the X chromosome, are implicated in tumor progression and poor patient outcomes.
Purpose of the Study:
- To investigate the tumorigenic properties of CT-X genes on the X chromosome.
- To explore the potential of targeting these CT-X genes with functional inhibitors for cancer therapy.
- To assess the impact of specific CT-X gene inhibition on melanoma cell behavior.
Main Methods:
- Utilized small interfering RNA (siRNA) to specifically target GAGE, SSX, and XAGE1 genes.
- Conducted cell proliferation, migration, invasion, and clonogenic survival assays.
- Employed melanoma cell lines, known for high CT antigen expression.
Main Results:
- siRNAs targeting GAGE and XAGE1 significantly inhibited melanoma cell migration and invasion.
- siRNAs targeting SSX4 and XAGE1 reduced the clonogenic survival of melanoma cells.
- GAGE, XAGE1, and SSX4 demonstrated a role in melanoma cell progression.
Conclusions:
- GAGE, XAGE1, and SSX4 exhibit tumorigenic properties and contribute to melanoma progression.
- These CT-X genes represent potential therapeutic targets for melanoma and other malignancies.
- Targeting CT-X genes via siRNA or other inhibitors could be a viable strategy in cancer treatment.
